# Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

> **NCT00617656** · PHASE3 · TERMINATED · sponsor: **Spanish Lung Cancer Group** · enrollment: 382 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- BRCA1 Mutation

## Interventions

- **DRUG:** Cisplatin, Docetaxel
- **DRUG:** Gemcitabine, Cisplatin
- **DRUG:** Docetaxel, Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00617656
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 382 (ACTUAL)
- **Why stopped:** No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental arm over the control arm- would not be confirmed.
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617656, "Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00617656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*